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Purpose: To define gene expression changes associated with diabetic retinopathy in a mouse model using next generation
sequencing, and to utilize transcriptome signatures to assess molecular pathways by which pharmacological agents inhibit
diabetic retinopathy.
Methods: We applied a high throughput RNA sequencing (RNA-seq) strategy using Illumina GAIIx to characterize the
entire retinal transcriptome from nondiabetic and from streptozotocin-treated mice 32 weeks after induction of diabetes.
Some of the diabetic mice were treated with inhibitors of receptor for advanced glycation endproducts (RAGE) and p38
mitogen activated protein (MAP) kinase, which have previously been shown to inhibit diabetic retinopathy in rodent
models. The transcripts and alternatively spliced variants were determined in all experimental groups.
Results: Next generation sequencing-based RNA-seq profiles provided comprehensive signatures of transcripts that are
altered in early stages of diabetic retinopathy. These transcripts encoded proteins involved in distinct yet physiologically
relevant disease-associated pathways such as inflammation, microvasculature formation, apoptosis, glucose metabolism,
Wnt signaling, xenobiotic metabolism, and photoreceptor biology. Significant upregulation of crystallin transcripts was
observed in diabetic animals, and the diabetes-induced upregulation of these transcripts was inhibited in diabetic animals
treated with inhibitors of either RAGE or p38 MAP kinase. These two therapies also showed dissimilar regulation of some
subsets  of  transcripts  that  included  alternatively  spliced  versions  of  arrestin,  neutral  sphingomyelinase  activation
associated factor (Nsmaf), SH3-domain GRB2-like interacting protein 1 (Sgip1), and axin.
Conclusions: Diabetes alters many transcripts in the retina, and two therapies that inhibit the vascular pathology similarly
inhibit a portion of these changes, pointing to possible molecular mechanisms for their beneficial effects. These therapies
also changed the abundance of various alternatively spliced versions of signaling transcripts, suggesting a possible role
of alternative splicing in disease etiology. Our studies clearly demonstrate RNA-seq as a comprehensive strategy for
identifying disease-specific transcripts, and for determining comparative profiles of molecular changes mediated by
candidate drugs.
Diabetes has emerged as a major worldwide public health
concern, and the number of diabetics is estimated to exceed
400 million by the year 2030 [1]. A side effect of diabetes,
namely  diabetic  retinopathy,  is  also  a  leading  cause  of
blindness  in  working  age  adults  (NIH  MedlinePlus  the
Magazine).  Several  approaches,  including  good  glycemic
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control, use of blood pressure medications, and lipid control,
have  been  demonstrated  to  inhibit  diabetic  retinopathy  in
clinical trials, but many patients are not able to maintain these
regimens  over  the  long-term.  Thus,  additional  therapeutic
approaches  are  continuously  being  sought.  Several
experimental  therapies  that  include  vitamin  E,  aspirin,
aminoguanidine,  or  inhibitors  of  receptor  for  advanced
glycation endproducts (RAGE) and p38 mitogen activated
protein (MAP) kinase [2–6] have shown positive effects at
inhibiting the development of diabetic retinopathy lesions in
laboratory animals, but the underlying molecular mechanisms
are not clear. Given their importance in cellular metabolism
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1123and  regulatory  processes,  these  therapeutic  agents  are
expected  to  target  distinct  pathways  either  directly  or
indirectly. Therefore, identification of the targets of these
drugs  might  assist  in  characterizing  their  molecular  side
effects.
Molecular  changes  accompanying  the  progression  of
disease can now be determined by several approaches. Gene
expression microarray analysis has been widely used during
the past decade for characterizing complete transcriptomes
[7–9] and it has yielded global profiles of whole retina or
retinal cell types in both wild type and disease models [10–
18].  A  comparison  of  the  expressed  complement  of  the
genome between normal and diabetic retinas has indicated
altered  abundance  of  transcripts  involved  in  several  key
pathways [19,20]. Although microarray strategies have been
successful  in  describing  disease-  or  phenotype-associated
expression changes, hybridization-based profiling approaches
suffer from technical variations that are difficult to control.
For this reason, many expression changes cannot be validated
by  quantitative  reverse  transcription  polymerase  chain
reaction  (qRT–PCR)  [21].  In  addition,  relevant  causative
expression changes, such as alternatively spliced variants of
transcripts and the expression of novel transcripts in disease
samples,  may  not  be  comprehensively  captured  because
specific probe sets may not be included on the particular
microarrays being used.
Next  generation  sequencing  based  on  the  RNA
sequencing (RNA-seq) approach is now gaining prominence
as  a  means  of  accurate  qualitative  and  quantitative
characterization of the expressed complement of a genome
[22,23]. This method provides millions of sequences from
expressed  RNA  molecules  and  can  provide  relatively
unambiguous definition and abundance of transcripts in a
given specimen. RNA-seq is therefore expected to reveal a
better representation of the transcriptome, and this strategy is
also more amenable for the analysis of alternatively spliced
transcripts.
We have recently demonstrated the high accuracy and
sensitivity of RNA-seq technology with microarray and qRT–
PCR methods by profiling the neural retina specific leucine
zipper deficient (Nrl−/−) retina [24]. In this paper, we define
the changes occurring in the entire retinal transcriptome of
streptozotocin (STZ)-induced diabetic mice compared to wild
type mice. We also attempt to identify relevant molecular
signatures and cellular pathways, with the goal of examining
the impact of inhibitors of RAGE and of p38 MAP kinase, two
candidate  drugs  that  inhibit  retinopathy  in  experimental
models.  Our  results  indicate  that  these  inhibitors  induce
common, as well as unique, molecular changes that may assist
in determining the efficacy and/or side effects of candidate
drugs.
METHODS
Streptozotocin-induced  diabetes  in  mice:  All  animal
experiments conformed to the ARVO Resolution on the Use
of Animals in Research and were approved by the Animal
Care  and  Use  Committee  of  Case  Western  University.
Diabetes  was  induced  in  C57BL/6  mice  (Jackson
Laboratories,  Bar  Harbor,  ME)  with  streptozotocin  and  a
corresponding number of weight and age-matched animals
were  maintained  as  normal  controls.  Mice  received  five
sequential  daily  intraperitoneal  injections  of  a  freshly
prepared solution of streptozotocin (Sigma-Aldrich, St Louis,
MO) in citrate buffer (pH 4.5) at 60 mg/kg of bodyweight.
After hyperglycemia was verified at least three times during
the second week after streptozotocin administration, diabetic
mice were randomly assigned to remain as untreated diabetic
controls  or  were  administered  RAGE-Ig  fusion  protein
intraperitoneally at three different concentrations (10, 100,
and 300 µg per mouse) three times per week. Insulin was given
to  diabetics  as  needed  (0–0.3  units  of  neutral  protamine
Hagedorn (NPH) insulin subcutaneously, 0–3 times per week)
to prevent weight loss without preventing hyperglycemia.
The  RAGE  fusion  protein  (provided  by  L.  Brown,
Galactica Pharmaceuticals, Inc., Villanova, PA) consists of a
RAGE  ligand  binding  element,  a  heavy  chain
immunoglobulin of G4 isotype (IgG4) constant domain with
a  linker  connecting  the  ligand  binding  element  with  the
constant domain. The RAGE-Fc binds to all of the known
ligands of RAGE and acts as a competitive, negative regulator
of RAGE signaling by competing with the membrane-bound
receptor for binding of ligands. For the present studies, a
murine version of hRAGE was employed in which a G2a
isotype (IgG2a) constant domain (biologically equivalent to
IgG4  in  hRAGE)  was  used.  The  inhibitor  of  p38  MAPK
(PHA666859) was provided by Pfizer Research Laboratories
(Groton, CT). PHA666859 was mixed into powdered diet and
replaced  weekly,  and  food  consumption  was  measured  to
calculate the amount of drug consumed.
We have previously shown that both of these therapies
inhibit the development of early stages of diabetic retinopathy,
as determined by the abundance of acellular capillaries and
pericyte  ghosts  [3,25].  Glycated  hemoglobin  (GHb;  an
estimate  of  the  average  level  of  hyperglycemia  over  the
previous  2–3  months)  was  measured  by  affinity
chromatography (Glyc-Affin; Pierce, Rockford, IL) every 3
months in each animal, after an overnight fast . Bodyweight
and average daily food consumption were measured weekly.
Experimental variations were reduced by CO2 asphyxiation of
all animals at 8 months of diabetes between 2 – 4 PM
Isolation of RNA: Retinal RNA was extracted with Trizol
reagent  [26,27].  Three  independent  retina  samples  were
obtained from groups of animals that were normal, diabetic,
treated with RAGE inhibitor, and treated with p38 MAPK
inhibitor. The RNA was quantified by absorbance at 260 nm
in a spectrophotometer and its integrity was determined using
an Agilent Bioanalyzer (Santa Clara, CA) [28].
Illumina RNA-seq: Independent RNA samples were used for
the  preparation  of  cDNA  libraries  using  an  mRNA-seq
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1124Sample Preparation Kit (Illumina, San Diego, CA). Briefly,
double stranded cDNA was prepared by random hexamer
priming and reverse transcription of chemically sheared total
RNA (2 µg). The double stranded cDNA was ligated with
adaptor sequences required for bridge amplification using the
Illumina flow-cell, and the ligated DNA was amplified before
library assessment and quantitation using the BioAnalyzer
DNA-1000 chip (Agilent). Cluster generation of 10 pM loads
of a single mRNA-seq library per lane was performed on the
Cluster  Station  using  an  Illumina  Single  Read  Cluster
Generation Kit v4 (Illumina). Sequence-by-synthesis single
reads of 54 base length using the SBS Sequencing Kit v4
(Illumina) were generated on the Genome Analyzer IIx. This
instrument runs real-time analysis SCS2.4 software (Illumina)
for base calling.
Real-time qPCR: Quantitative RT–PCR was performed using
a Genetic Analyzer 7900HT (Life Technologies, Carlsbad,
CA)  with  Taqman  or  SYBR  green  assays,  as  previously
described  [24].  Briefly,  total  RNA  (1  µg)  was  reverse
transcribed by Superscript II reagents (Life Technologies,
Carlsbad,  CA)  primed  with  oligo(dT)20.  The  cDNA  was
diluted fivefold and one microliter was used as template in
subsequent qRT–PCR reactions. The integrity of the PCR
reaction was verified by melt curve analysis. The results of
amplifications  of  three  biologic  replicates,  performed  in
triplicate,  were  averaged  to  produce  the  qRT–PCR  data.
Changes in gene expression were determined by the ddCT
method  using  the  levels  of  HPRT  (hypoxanthine  guanine
phosphoribosyl transferase) transcript for normalization.
Bioinformatics  analysis  of  RNA-seq  data:  The  cDNA
sequences captured on the Illumina platform were analyzed
using the following workflows.
(1) Transcript isoform level analysis was performed by
aligning the 54 base cDNA reads against the reference genome
mm9 build using a Burrows-Wheeler transform based short
read  aligner  (BWA)  [29],  and  the  aligned  reads  were
visualized using Integrated Genome Viewer [30]. The read
alignment files were imported into Partek Genomics Suite
(Partek® Genomics SuiteTM. 6.3 ed. St. Louis, MO: Partek
Inc.; 2008) and RPKM (reads per kilobase of exon model per
million  mapped  reads)  counts  for  each  of  the  28,157
transcripts defined in the UCSC refflat annotation file were
calculated. A stringent filtering criterion with RPKM value of
1.0 [31] was used to obtain 16,577 expressed transcripts. The
RPKM values of filtered transcripts were log-transformed
using log2 (RPKM + offset) with an offset value of 1.0. This
filtering  protocol  reduced  the  number  of  transcripts  from
28,157  to  16,577  for  further  analyses.  Fold  changes  in
transcript  expression  and  p-values  were  computed  using
ANOVA, and significantly altered transcripts were selected
by applying fold change-cutoff of 1.5 and/or p-value cutoff of
0.05. Gene Ontology (GO) pathways that were significantly
enriched between each of the sample pairs were identified
using ExPlain tool from Biobase International, Beverly, MA.
(2) Alternatively, gene level analysis was performed by
aligning the filtered reads to the mouse reference genome
build mm9 using the ELAND (Efficient Local Alignment of
Nucleotide  Data)  algorithm  (Anthony  J  Cox,  Solexa  Ltd
Saffron,  Walden,  UK).  First,  raw  and  RPKM  normalized
counts were calculated for gene models (as defined in UCSC
RefGene).  Subsequently,  we  applied  SAM  (significance
analysis  of  microarrays)  to  gene  level  RPKM  to  identify
RNAs with a fold change greater than 1.5 and false discovery
rate (FDR) of less than 25%. Briefly, the boundaries of exons
were obtained from the RefGene database (Genome), and the
numbers of mapped reads on each exon were calculated. The
mapped reads as RPKM indicated the expression level of
exons, and this value was used to calculate the Log base 2 of
the average (or maximum) expression level of exons for each
gene. For this alternative analysis, a less stringent cutoff of
0.5 RPKM was used to select expressed genes for further
analysis.
Alternatively spliced exons: Alternatively spliced transcripts
were detected using the AltAnalyze tool [32], which employs
de novo splice junctions to predict alternative splicing events
based  on  the  reads  spanning  the  splice  junctions.  First,
TopHat  [33]  was  run  independently  on  sequence  reads
obtained for each of the 12 RNA samples to identify all novel
splice junctions. Second, we combined all predicted splice
junctions into a master file and used this as an input option,
together with the Ensembl mouse gene transfer format (GTF)
annotation file, for a second iteration of TopHat runs on each
of the 12 samples. Finally, these 12 junction files were used
as input in AltAnalyze to detect alternative splicing using the
analysis  of  splicing  by  isoform  reciprocity  (ASPIRE)
algorithm.
Briefly, we calculated the number of sequences mapping
to a specific exon junction and the numbers of sequences
mapping to junctions as well as exons of that specific gene.
These two numbers were then used to calculate the fraction of
the junction containing sequences relative to the mean of
abundance of sequences of all junctions and exons in the gene.
The procedure was applied to each reciprocal isoform pair
(i.e., an isoform that includes a specific exon and an isoform
in which that exon is excluded). The inclusion and exclusion
ratios were then used to compute the value for ΔI. The details
of  these  protocols  have  been  described  in  AltAnalyze
workflow [32], as adapted from ASPIRE algorithm [34]. The
ratios described above were used to calculate p values for the
sample ASPIRE scores relative to controls, and to determine
false-discovery rate p values [35].
RESULTS
Glycemia: Diabetic mice from all experimental groups had
levels  of  GHb  and  blood  glucose  that  were  significantly
greater  (p<0.05)  than  levels  found  in  appropriately  age-
matched  nondiabetic  controls.  Average  GHb  for  the
nondiabetic control (N), diabetic control (D), diabetic plus
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RAGE-Fc fusion protein (D + mRAGE-Fc) groups over the
entire duration of study are listed in Table 1. Although diabetic
mice did not gain weight at the normal rate, none of the
animals lost bodyweight, and all of the animals appeared
clinically healthy. These results indicate that the therapies
involving inhibitors of RAGE and p38 MAP kinase do not
alter the diabetic status of the animals.
Raw read counts and transcripts in sequenced samples: Total
raw reads for various samples were in the range of 27.8–35.5
million, which represented ~1.6 gigabases of sequences for
each sample. Efficient Local Alignment of Nucleotide Data
(ELAND)  and  Burrows-Wheeler  Alignment  (BWA)  tools
allowed the alignment of 13.8- 20.9×106 reads from various
samples to mouse genome sequence database (build mm9).
These  aligned  reads  were  subsequently  analyzed  by
significance analysis of microarrays (SAM) or ANOVA. The
sequence alignment files were imported into PARTEK, and
the  normalized  values  for  numbers  of  RPKM  for  28,157
transcripts defined in the UCSC refflat file were obtained.
Among  these  sequences  obtained  from  nondiabetic  and
diabetic  animals,  16,231  transcripts  had  RPKM  values  of
greater  than  one,  and  included  rhodopsin  (Rho),  guanine
nucleotide binding protein (Gnat1), retinol binding protein
(Rbp1),  phosphodiesterase  6A  (Pde6a),  and  guanine
nucleotide  binding  protein  (Gngt1)  as  the  most  abundant
sequences specific to photoreceptor cells. Similarly, the list
also contained other less abundant transcripts such as paired-
like  homeodomain  3  (Pitx3),  PDZ  and  LIM  domain
1(Pdlim1),  and  meteorin  (Metrnl).  The  presence  of  these
highly abundant as well as rare transcripts in the data set
demonstrates that the library preparation and data analysis
methods did not introduce any undesirable bias.
Comparison  of  transcript  differences  revealed  by  two
analyses: We analyzed the sequence data using ELAND-
SAM and BWA-ANOVA methods, and compared the results
to confirm method-specific changes in transcript abundance
in the various groups of animals. Differential expression in
diabetic and normal animals revealed the top 100 transcripts
shortlisted  by  the  two  methods,  as  shown  in  Table  2
(Appendix 1). Of these 100 transcripts, 81 are present in both
data sets (Figure 1) including a variety of crystallin genes.
However,  UDP-glucuronosyl  transferase  transcripts  were
detected only by the ELAND-SAM method. A significant
difference was also noted in the fold-changes indicated by the
two  methods.  These  differences  can  be  attributed  to
differences in the alignment algorithms, filtering criteria, and
calculation of differential gene expression between the two
methods,  and  demonstrate  that  altered  abundance  of
transcripts can be detected by either one of these two methods.
Validation  of  significantly  altered  transcripts:  Some
representative transcripts were chosen for validation based on
the magnitude of the changes in their abundance and their
involvement  in  various  pathways.  We  performed  Taqman
real-time PCR to validate 11 transcripts, including Cryga-
crystallin  gamma  A,  Crygb-crystallin  gamma  B,  Dct-
dopachrome tautomerase, Egr-early growth response, FABP-
fatty acid binding protein, Lgsn-lengsin, Lim2-lens intrinsic
membrane protein, Nr2c2ap-nuclear receptor 2C2-associated
protein, retinal pigment epithelium 65 Kd protein (Rpe65),
Sfrp1-secreted  frizzled-related  protein,  and  wingless  type
MMTV integration site, member 7b (Wnt7b). The level of
each of these transcripts corresponded to the pattern revealed
by RNA-seq, and indicated significant changes in the levels
of these transcripts between diabetic and normal mice (Figure
2). However, the magnitude of change observed by RT–PCR
was  not  identical  to  the  results  of  RNA-seq.  The  non-
correspondence  of  magnitude  reflects  the  differences  in
sensitivities of the RNA-seq and Taqman assays, which are
two inherently different strategies.
A  few  additional  transcripts  (Cdh3-cadherin,  Fgf2-
fibroblast growth factor, Lrat-lecithin retinol acyltransferase,
Mnd1-meiotic nuclear divisions 1 homolog, Rgr-retinal G-
protein  coupled  receptor,  and  Sema3c-semaphorin)  were
chosen for validation with SYBR green based real-time qPCR.
All of these transcripts were significantly altered in diabetic
mice (Figure 3). As stated for Taqman qPCR validation, the
correspondence between RNA-seq and SYBR green qPCR
was comparable but not identical.
Transcripts, pathways and gene ontology (GO) categories are
altered  in  retinas  isolated  from  diabetic  animals:  The
application of SAM and a false discovery rate of 25% for the
data set revealed greater than 1.5 fold alterations in the levels
of 173 transcripts. Alternative analysis with BWA-ANOVA,
however, indicated alterations of greater than 1.5 fold in 298
TABLE 1. GLYCEMIC STATUS OF CONTROL AND DRUG-TREATED ANIMALS OVER THE 8 MONTHS OF THE STUDY.
Control/Treatments* Glucose Glycated hemoglobin (GHb)
Nondiabetic Controls (N) 130+8 3.0+0.1
Diabetic Controls (D) 400+21 10.4+0.9
Diabetic plus p38 MAPK inhibitor (D+PHA666859) 411+32 10.3+0.6
Diabetic plus murine RAGE-Fc Fusion Protein (D + mRAGE-Fc) 393+31 10.6+0.7
        *The values are reported as mean ± standard deviation, and were calculated for 10, 7, 7, and 8 animals in the four groups,
        respectively.
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1127transcripts.  Among  several  GO  categories,  significantly
altered transcripts revealed by either of the two methods were
grouped together as structural constituents of eye lens, visual
perception,  sensory  perception  of  light  stimulus,  eye
development, structural molecule activity, microsomes, the
vesicular  fraction,  and  glucuronosyl  transferase  activity.
Changes  were  also  observed  in  transcripts  involved  in
inflammatory  pathway,  apoptosis,  microvasculature,  Wnt
signaling,  photoreceptors,  and  neural  cell  function.  The
alterations  in  the  levels  of  these  transcripts  are  described
below.
Crystallins, a major class of retinal genes, are altered in
diabetic retinopathy: More than 20 variants of crystallins have
been  detected  in  the  retina.  Of  these,  13  transcripts  were
increased by greater than 1.6 fold (Table 3). The levels of
Cryaa,  Cryba1,  Cryba2,  Cryba4,  Crybb1,  Crybb2,  and
Crygs in diabetic animals were elevated by >9.0 fold, whereas
the abundance of Cryab, Crygb, Crygc, Crygd, and Crygn in
diabetic animals varied between 1.6 and 6.6 fold compared to
Figure 1. Differentially expressed gene
sets were obtained by employing either
significance  of  microarray  analysis
algorithm or ANOVA method. The gene
sets  were  applied  as  described  in
Methods section and the genes unique
and  common  in  the  two  sets  are
indicated.
Figure 2. TaqMan real-time quantitative
polymerase  chain  reaction  (qPCR)
validation was performed for selected
transcripts.  The  transcripts  were
amplified  as  described  in  Methods
section. Three technical replicates were
performed for three biologic replicate
samples  of  RNA  isolated  from
nondiabetic  animals,  diabetic  animals
and diabetic animals treated with either
the inhibitor of receptor for advanced
glycation  endproducts  (RAGE)
indicated as RI, or the inhibitor of p38
mitogen  activated  protein  kinase
(MAPK) designated as p38. The bars
(left  to  right)  represent  samples
corresponding  to  diabetic  animals,
diabetic  animals  treated  with  RAGE
inhibitor, and diabetic animals treated
with p38 MAPK inhibitor, respectively.
Fold  increase  was  calculated  with
respect to nondiabetic controls.
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1128non-diabetic controls. These transcript changes were detected
by both analysis methods.
Alterations in Wnt signaling transcripts: Altered levels were
observed for 14 transcripts that are either directly involved in
Wnt signaling pathway or are targets of Wnt signaling (Table
4). While Sfrp1 and Wnt7b levels in diabetic animals increased
by 3.9 and 2.9 fold, Wnt7a and Mfrp were upregulated by more
than 2.0 fold. The increase in the levels of Wnt5b and axin,
and decrease in Wisp 1 and Wnt2b transcripts were marginal.
The levels of a few target genes of Wnt signaling such as
FRAT2, BMP4, Cldn1, and Cldn2 were also altered.
Transcripts  involved  in  microvasculature  and  the
inflammatory pathway: Endothelin and VEGF were among
the vascular transcripts detected in the retina. The levels of
Edn2 decreased by 1.4 fold, whereas an increase of 1.4 fold
was observed in the levels of Edn3 (Table 5). The levels of
other vasculature related genes were marginally altered in
diabetic  animals.  Alterations  were  also  observed  in  the
abundance  of  inflammation  associated  transcripts,  namely
Ltbp1, Bmp4, Hspb1, CD44, C1qtnf5, Ifitm1, and Islr, which
varied between 1.5 and 2.2 fold in diabetic animals (Table 6).
Transcripts involved in apoptosis: We analyzed a variety of
pro-apoptotic and anti-apoptotic transcripts as well as other
transcripts  that  influence  the  apoptosis  pathways.  A
significant increase was observed in the levels of Dapl1 and
Bid1,  while  the  levels  of  Fads3,  Fas,  and  Bag5  showed
marginal alterations. An appreciable decrease was also noted
in the levels of Trafip3, Tnfsf13, Tnfrsf18, and Casp7 (Table
7).  It  warrants  mention  that  these  transcripts  were  not
shortlisted when the FDR and p-value cut-off were applied to
the  data  analysis.  Given  the  importance  of  apoptosis  in
diabetic retinopathy [36,37], these genes were specifically
analyzed from the master list of sequenced tags and were
found to have altered levels in the diabetic animals.
Transcripts  involved  in  neuronal  functions  and
photoreceptors:  The  list  of  differentially  expressed  genes
obtained by applying stringent threshold parameters did not
contain any transcripts involved in neuronal development or
signal  transduction.  However,  a  review  of  the  transcript
master list, without applying rigorous statistical significance,
revealed changes in transcripts encoded by polycomb genes
(Pcgf),  acetyl  choline  receptor  genes  (Chrn),  muscarinic
cholinergic  receptor  genes  (Chrm),  potassium  channels
(Kcnq),  glutamate  receptor  genes  (Grin),  solute  carrier/
transporter genes (Slc), and the fasciculation and elongation
gene (Fez) (Table 8). Similar review revealed decreased levels
of transcripts involved in the development and function of
photoreceptors. These transcripts included cyclic nucleotide
gated  channel  (Cngb3),  arrestin  (Arr),  guanine  nucleotide
binding  protein  (Gnb3),  and  phosphodiesterase  (Pde6h).
Marginal  decreases  were  also  noticed  in  photoreceptor-
specific transducin (Gnat2) and Crxos1. However, the levels
of Nrl, Crx, and Nr2e3 remained relatively unchanged (Table
9).
Altered  expression  of  genes  encoding  glucuronosyl
transferases in diabetic retinopathy: A significant increase
Figure 3. Cyanine (SYBR) green real-
time  quantitative  polymerase  chain
reaction  (qPCR)  validation  was
performed for selected transcripts. The
transcripts were amplified as described
in  Methods  section.  Three  technical
replicates  were  performed  for  three
biologic  replicate  samples  of  RNA
isolated  from  nondiabetic  animals,
diabetic  animals  and  diabetic  animals
treated with either inhibitor of receptor
for  advanced  glycation  endproducts
(RAGE) indicated as RI, or an inhibitor
of p38 mitogen activated protein kinase
(MAPK) designated as p38. The bars
(left  to  right)  represent  samples
corresponding  to  diabetic  animals,
diabetic  animals  treated  with  RAGE
inhibitor, and diabetic animals treated
with p38 MAPK inhibitor, respectively.
The  error  bars  represent  standard
deviation from the mean value (n=9).
The levels of transcript in diabetic and
treated  animals  were  determined
relative  to  the  levels  present  in
nondiabetic controls.
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1136was  observed  in  transcripts  for  members  of  the  UDP-
glucuronosyl  transferase  gene  family  during  diabetic
retinopathy. The protein products of these genes are primarily
responsible for the metabolism of xenobiotics. In particular,
UGT1A5,  UGT1A10,  UGT1A1,  UGT1A9,  UGT1A2,
UGT1A7C,  UGT1A6A,  and  UGT1A6B  transcripts  were
elevated by greater than 3.0 fold in diabetic animals (Table
10). These transcripts were detected in analyses performed by
the ELAND-SAM method at the gene level with a FDR cutoff
of 25%, but were absent in the list of transcripts generated by
transcript isoform level BWA-ANOVA analysis at a p value
cutoff of less than 0.05.
Rhodopsin-retinol  pathway  altered  in  diabetic  mice:
Rhodopsin-retinol  pathway  transcripts  showed  increased
levels for lecithin retinol acetyl transferasease, transthyretin,
retinol  binding  protein,  and  Stra6  (stimulated  by  retinoic
acid). However, decreases occurred in the levels of transcripts
corresponding to retinoic acid metabolism enzyme Cyp26a1,
retinol dehydrogenase, and rhodopsin phosphorylating GPCR
kinase (Grk4).
Pathways related to altered metabolism in diabetic mice:
Transcripts directly/indirectly related to glycemic pathway
showed  marginal  increases  in  the  case  of  glycerol-3-
phosphate dehydrogenase and insulin secretion modulating
Trpm4 protein, whereas transcripts levels decreased slightly
for a glycogen interacting protein Trim7 and for insulin-like
growth factor binding proteins Igfbp3 and Igfbp5.
Alternative splicing of genes in diabetic retinopathy: The
RNA-seq method provides the identity of transcripts that have
yielded an unambiguous sequence. Some of the sequence
reads, which span exon boundaries, can be analyzed to predict
alternatively spliced transcripts. We identified 55 genes that
were alternatively spliced in the retina of diabetic animals
(Table 11). The alternative splicing events in these genes were
detected by selecting transcripts with a RPKM cutoff of 3.0
and using ASPIRE’s ΔI cutoff of 0.2, which indicates a 20%
change in exon inclusion. This threshold of ΔI has been shown
to  yield  accurate  representations  of  alternatively  spliced
versions of transcripts [34].
It warrants mention that alternative splicing of transcripts
is also prevalent in the retinas of normal animals. The 55
alternatively  spliced  transcripts  therefore  represent  either
novel  spliced  versions  or  spliced  isoforms  with  altered
abundance in diabetic animals, which suggests an association
of alternative splicing with diabetic retinopathy. Noteworthy
among these transcripts were those involved in neuronal cell
survival,  neural  differentiation,  apoptosis,  endocytosis,
intracellular  transport,  glucose  metabolism  and  insulin
impairment,  G-protein  coupled  receptor  signaling,  and
mRNA  processing.  Specifically,  alternative  splicing  of
arrestin  (Arr),  interphotoreceptor  matrix  proteoglycan
(Impg2), and transient receptor membrane potential cation
channel provide tentative evidence for the effects of diabetic
retinopathy on the activity and integrity of photoreceptor cells
in the retina.
Responsiveness to treatments and molecular side effects of
therapeutic  intervention  with  candidate  drugs:  We  have
characterized  the  molecular  responsiveness  of  animals  to
treatments as positive, negative, or as side effects, based on a
comparison with wild type mice. We define positive effects
of drugs as a reversal of transcript levels toward normalcy,
and negative effects as changes in transcript levels of treated
animals that are greater than those seen in the diabetic animals
when compared to wild type animals. If a transcript remains
unchanged in retinas from diabetic animals and the therapy
leads to a significant change in its abundance, this is classified
as a side effect.
Treatments with inhibitors of RAGE and p38 MAPK
inhibited diabetes-induced changes (positive effects) and also
exacerbated other changes (negative effects; Table 3, Table 4,
Table 5, Table 6, Table 7, Table 8, Table 9, and Table 10).
Both  inhibitors  blocked  the  diabetes-induced  changes  in
levels  of  all  crystallin  transcripts  and  the  levels  of  UDP-
glucuronosyl  transferases.  Both  inhibitors  worked  well  in
preventing  the  changes  in  the  levels  of  Wnt  pathway
transcripts or apoptosis transcripts, but the RAGE-inhibitor
appeared to work positively on a greater number of transcripts,
as was the case for transcripts of inflammatory pathways.
Surprisingly,  photoreceptor  transcripts  were  adversely
affected in animals treated with either of these drugs. Of the
837 transcripts that were altered by greater than 1.5 fold in
diabetic mice or in any one of the treatments, 379 transcripts
were further exacerbated by RAGE inhibitor. The treatment
with p38 MAPK inhibitor, on the other hand, caused further
adverse  exacerbations  in  535  transcripts.  Whether  these
exacerbations of transcript levels by drugs were beneficial or
detrimental is not known at present.
Similar  analyses  were  also  performed  with  the  data
related  to  alternative  splicing  (Figure  4).  Comparison  of
diabetic versus nondiabetic, RAGE inhibitor-treated diabetic
versus nondiabetic and p38 MAPK inhibitor-treated diabetic
versus  nondiabetic  animals  led  to  the  identification  of
alternatively  spliced  transcripts  specific  to  each  group  of
animals (Table 11, Table 12, and Appendix 2). Some notable
alternatively spliced transcripts in diabetic animals included
doublecortin-like  kinase  Dclk3,  death  effector  domain
Dedd2, dynein Dync1li2, interphotoreceptor matrix protein
Impg2, ankyrin 2, arrestin 3, coiled-coil domain containing
Ccdc64,  G-protein  coupled  receptor  Gprasp2,  Nsmaf,
dynactin 6, and whirlin (Table 11). Among the transcripts
responsive to RAGE inhibitor were photoreceptor specific
gene arrestin, Nsmaf transcript involved in apoptosis, and
endocytosis transcript Sgip1. The exacerbated levels of 76
alternatively  spliced  transcripts  in  p38  MAPK  inhibitor-
treated animals included the Wnt pathway transcript Axin1
and  its  target  gene  Cldn1,  opsin  transcript  Opnm1w,
Molecular Vision 2012; 18:1123-1146 <http://www.molvis.org/molvis/v18/a119> © 2012 Molecular Vision
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1138Mapk8ip3,  peroxisomal  transcript  Pex16,  cilia  transcript
Cep164, and ocular regulator Pax6 (Table 12 and Appendix
2). A comparison of alternatively spliced transcripts revealed
12 transcripts common among nondiabetic animals, diabetic
animals, diabetic animals treated with RAGE inhibitor, and
diabetic animals treated with p38 MAPK inhibitor (Figure 4).
Among  others,  these  genes  included  G-protein  coupled
receptor associated sorting protein, kinesin family member
1A, nuclear receptor co-repressor, phospholipase A2, and zinc
finger protein 444. Although the summary presented in Figure
4 does not allow us to decipher the mechanisms of these
therapies,  the  results  suggest  that  the  changes  in  splicing
patterns in response to therapy may reflect the positions of p38
MAP kinase and RAGE in the cell signaling pathways relative
to each other.
DISCUSSION
This is the first report to describe the application of RNA-seq
for  comprehensive  sequencing  of  transcripts  in  a  diabetic
retinopathy model and for evaluating the efficacy of candidate
drugs. The RNA-seq methodology has allowed accurate and
quantitative  identification  of  molecular  signatures.  The
quantitative  RT–PCR  data  (by  TaqMan  or  SYBR  Green)
validated the expression changes for all 15 transcripts that
were examined. Interestingly, the rank order of differentially
TABLE 11. ALTERNATIVELY SPLICED TRANSCRIPTS IN DIABETIC ANIMALS
Gene symbol Gene name Gene symbol Gene name
Abca8a ATP-binding cassette Agtpbp1 ATP/GTP binding protein
Ankrd39 ankyrin repeat domain Ank2 ankyrin 2, brain
Apip APAF1 interacting Dus1l dihydrouridine synthase
Bdh1 3-hydroxybutyrate dehydrogenase Eif4g3 eukaryotic translation initiation
Cltb clathrin Epb4.1l2 erythrocyte protein
Commd6 COMM domain Fam193b family with sequence similarity193
Dclk2 doublecortin-like kinase Hook2 hook homolog 2
Dedd2 death effector domain Pcmtd2 protein O-methyltransferase
Dync1li2 dynein Tpm3 tropomyosin 3,
Fam161a family with sequence similarity Arr3 arrestin 3, retinal
Fam184a family with sequence similarity184 Gprasp2 G protein-coupled receptor
Ggps1 geranylgeranyl diphosphate synth Gse1 genetic suppressor element
Gripap1 GRIP1 associated protein Nsmaf neutral sphingomyelinase
Impg2 interphotoreceptor matrix protein Sgip1 SH3-domain GRB2-like
Plekha6 pleckstrin homology domain Ubtf upstream transcription factor
Ppie peptidylprolyl isomerase E Unc79 unc-79 homolog
Ptprf protein tyrosine phosphatase Ccdc64 coiled-coil domain containing
Samhd1 SAM domain and HD domain Cugbp2 CUGBP, Elav-like
Scamp3 secretory carrier mem protein Dctn6 dynactin 6
Smc5 structural maintenance of chrom Mak male germ cell-associated kinase
Sorbs1 sorbin and SH3 domain Mare nitrogen permease regulator-like 3
Trpm1 transient receptor cation channel Scarb1 scavenger receptor class B,
Tsc2 tuberous sclerosis 2 Slc30a9 solute carrier family 30 (Zn)
Zcrb1 zinc finger CCHC-type Trnau1ap tRNA selenocysteine 1 protein
Zmiz2 zinc finger, MIZ-type Whrn whirlin Gene
Figure 4. Unique and common splice
forms  of  transcripts  are  present  in
various groups of animals. The splice
variants  from  various  samples  were
compared and the numbers of transcripts
unique to a specific experimental pair or
common to two or more experimental
pairs are indicated.
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1140expressed  transcripts  (as  a  consequence  of  diabetes  or
treatment  with  drugs)  differed  between  the  two  analysis
methods used. The ELAND-SAM method used gene model
annotations (RefGene) from UCSC, while the BWA-ANOVA
method used the transcript model annotations (refflat) from
UCSC. However, the transcripts revealed by both methods of
analyses  were  verifiable  by  real-time  PCR  and  thus  the
validity of both methods was supported. The validation of the
RNA-seq platform for comprehensive transcriptome analysis
has recently been described by Brooks et al. [24]. Given the
growing use of next generation sequencing platforms, the
development of additional analytical tools in the future should
allow even better description of RNA-seq data.
As predicted, we observed changes in a variety of retinal
transcripts due to diabetes. Some of these changes have been
found to influence glucose metabolism or to alter the levels of
hormone and hormone receptors in other tissues; these include
glycerol-3-phosphate  dehydrogenase,  galanin  receptor
(Galr2)  involved  in  G-protein  coupled  receptor  signaling,
transient  receptor  (Trpm4)  involved  in  insulin  secretion,
insulin  like  growth  factor  binding  proteins  (Igfbp3  and
Igfbp5), the kinesin family of proteins, and calpain. Since
vascular cells occupy such a small portion of the retina, the
majority of observed changes likely are due to changes in the
retinal  neuroglia.  Consistent  with  this  idea,  the  list  of
transcripts that were significantly altered in diabetes did not
contain transcripts corresponding to retinal vasculature, but
targeted analyses of specific transcripts (such as endothelin-2,
endothelin-3  and  VEGFB)  nevertheless  revealed  diabetes-
induced  alterations  of  1.1–1.4  fold  in  levels  of  these
transcripts.
Inflammation has been previously demonstrated to play
an important role in the pathogenesis of diabetic retinopathy
in animals [38,39]. Previous microarray profiling in a rat
diabetic retinopathy model indicated changes in the levels of
a variety of transcripts involved in inflammatory pathways
[19].  Our  RNA-seq  data  showed  many  inflammation-
associated genes with altered expression; these included C1q
TNF-related gene 5 (C1qtnf5), latent TGF-β binding protein
(Ltbp1), phospholipase (Pla2g2f), interleukin 17 receptor 7c
(Il17rc), and C4b. The changes in relatively few transcripts of
the inflammatory pathway by eight months of diabetes seen
in our study, when compared to changes reported at shorter
durations, might indicate that inflammation is most severe
early during the etiology of diabetic retinopathy, and that its
severity might diminish as the disease progresses.
A variety of transcripts were altered in late stage diabetes;
our  RNA-seq  data  identified  the  Wnt  signaling  pathway,
crystallins,  and  various  transcription  factors.  Significant
alterations  were  observed  in  the  abundance  of  transcripts
corresponding to Wnt7b, secreted frizzled receptor related
protein-1 (Sfrp1), dapper antagonist of β-catenin (Dact1), Wnt
inducible secreted protein-1 (Wisp1), and membrane frizzled
related protein (Mfrp). Modulation of the Wnt pathway has
been reported as a likely target for intervention for diabetic
retinopathy  [40],  and  Wisp1  is  known  to  upregulate  the
expression  of  the  anti-apoptotic  Bcl-X(L)  gene  [41].  In
addition to the involvement of Wnt pathway proteins in other
inflammatory  diseases  [42],  alterations  in  Wnt  signaling
proteins have been shown in a rat diabetic retinopathy model
[43].
We and others have previously observed a significant
upregulation  of  different  crystallin  transcripts  in  diabetic
retina  [44].  The  levels  of  fourteen  crystallins  increased
significantly in diabetic mice. These proteins were initially
characterized as structural components of the eye lens [45,
46], but expression of crystallins has been shown in other
tissues including the retina [47]. Crystallins that belong to the
small heat shock protein family have a non-structural role
[48],  and  retina-specific  elevated  levels  of
Cryaa,Cryba1,Crygs,Crybb2,Crygb,  and  Crygc  have  been
reported in experimental uveitis [49]. Cryaa was shown to
localize to photoreceptor cells in experimental uveitis, which
likely represents a function in these cells to protect against
apoptosis  [49].  Our  results  clearly  indicate  a  dramatic
upregulation of various crystallins in diabetic retinopathy and
suggest this to be a stress response, which may be similar to
the reported effects of increased levels of Hspb1 transcript in
retina  [50].  Post-translational  modifications  have  been
reported to alter chaperone activity of crystallins [51–53],
while  glycation  associated  with  aggregation  is  likely  to
compromise the protective effects of crystallins in diabetic
animals.  Transcriptional  upregulation  of  crystallins  may
therefore  possibly  represent  a  stress  response,  but  the
translated  proteins  may  be  rendered  dysfunctional  by
diabetes-induced  and  deleterious  post-translational
modifications and other crosslinking events.
The  deleterious  changes  to  the  retina  that  occur  in
diabetes are likely to be associated with alterations in the
levels of transcripts associated with apoptosis, survival, and
metabolic injury. Consistent with this hypothesis, we have
observed changes in a variety of transcripts associated with
apoptosis pathways. The metabolic injury to the neural retina
is suggested by the altered levels of transcripts that modulate
oxidative  stress  in  cells.  Changes  in  transcripts  such  as
cytochrome c oxidase, glutathione-S-transferase omega-1 and
omega-2,  microsomal  glutathione  S-transferase,  and
glutathione synthase indicate that cellular injury to the retina
occurs due to oxidative stress. While cytochrome oxidase is a
sink  for  molecular  oxygen  channeled  through  electron
transport  chain  in  mitochondria,  glutathione  synthase  and
glutathione-S-transferases are important components of redox
reactions.
The comparative analysis of gene level expression data
also revealed differential expression of UDP-glucuronosyl
transferases  in  diabetic  animals.  The  UDP-glucuronosyl
Molecular Vision 2012; 18:1123-1146 <http://www.molvis.org/molvis/v18/a119> © 2012 Molecular Vision
1141transferases metabolize a variety of xenobiotics, but they are
also important for reactions occurring in cellular metabolism,
such as those involving steroid hormones. We speculate that
these enzymes may possess some other signaling activities, in
line  with  the  reported  observation  that  UDP-glucuronosyl
transferase  2B17  depletion  led  to  downregulation  of  the
Mcl-1  gene  [54].  If  these  types  of  signaling  activities
associated with UDP-glucuronosyl transferases are involved
in the transcription of diabetic retinopathy-related genes, then
targeted inhibition of specific UDP-glucuronosyl transferases
might have therapeutic implications for diabetic retinopathy.
Numerous groups have been exploring ways to inhibit
diabetic retinopathy by blocking specific metabolic pathways.
Although  none  of  these  targeted  approaches  have  been
successful in the clinic to date, several candidate drugs are
being evaluated for efficacy. The alterations in the levels of
superoxide, nitric oxide, cyclooxygenase-2, VEGF, and NF-
κβ in the early stages of diabetic retinopathy are consistent
with the inflammation observed in retinal tissue. Our drug
studies suggest that diabetes-induced alterations observed in
inflammatory pathway transcripts are mediated in particular
via p38 MAPK [40,55,56]. Another metabolic consequence
of chronic hyperglycemia, in addition to inflammation, is the
accumulation of advanced glycation end products (AGEs)
[57]. These AGEs and other ligands are recognized by RAGE,
and  activated  RAGE  is  associated  with  a  variety  of
downstream consequences such as upregulation of VEGF and
NF-κβ,  and  increased  leucocyte  adhesion  in  retinal
microvascular endothelial cells, all of which are consistent
with inflammation. Importantly, inhibitors of RAGE and p38
MAPK have been shown to inhibit the development of early
stages of diabetic retinopathy in animals [3,25].
Since the phenotypic benefits of the two therapies are
similar,  assessing  their  efficacies  against  the  molecular
changes that they cause might provide important information.
We have tested these effects to determine whether the drug
prevents diabetes-induced changes in transcripts or further
exacerbates diabetes-induced changes in transcript levels. Our
data suggest that the RAGE inhibitor reversed the levels of a
large number of transcripts whose levels were significantly
altered in diabetic mice. Although the p38 MAPK inhibitor
seemed comparably effective at inhibiting the development of
diabetic  retinopathy,  it  did  not  inhibit  as  many  diabetes-
induced changes in levels of transcripts, in contrast to what
was seen with the RAGE inhibitor. One possible interpretation
of  this  difference  is  that  the  transcripts  normalized  by
inhibition of RAGE, but not p38 MAPK, are not critical for
the development of the lesions that characterize early diabetic
retinopathy. Interestingly, the p38 MAPK inhibitor caused
further exacerbations in many more diabetes-induced changes
in  transcript  levels  than  did  the  RAGE  inhibitor.  The
intracellular protein p38 MAPK is downstream of RAGE
[58] in one of the three pathways, such as PI3K, NF-kB, and
MAPK that are initiated by AGE. Thus, one might expect a
greater  number  of  altered  transcripts  upon  activation  of
RAGE, and reversal of transcript changes in animals treated
with the inhibitor of RAGE.
An  important  and  useful  outcome  of  the  RNA-seq
approach  was  the  identification  of  alternatively  spliced
transcripts during the development of diabetic retinopathy.
Disease specific alternatively spliced transcript variants are
shown  to  exist  in  various  conditions  [58,59],  and  our
experimental  studies  show  that  alternatively  spliced
transcripts  arise  as  diabetic  retinopathy  develops.
Characterization of alternatively spliced transcripts that are
specifically present or absent in a specific condition provides
another opportunity for therapeutic intervention of diabetic
retinopathy. Tocotrienol and EGCG are known to target splice
sites and to modulate the abundance of alternatively spliced
transcripts [60,61]. Exploration of the ability of these agents
to inhibit diabetic retinopathy will be an interesting avenue of
further research.
Reversal of the levels of alternatively spliced exons upon
treatments  also  provides  an  additional  validation  of  drug
efficacy.  Our  novel  finding  of  alternative  splicing  of
transcripts in diabetes raises the possibility that these changes
contribute to the pathogenesis of the retinopathy. From this
perspective,  the  identification  of  photoreceptor-specific
changes  in  arrestin,  Impg2,  and  Trpm1  raises  the  further
possibility of a contribution by photoreceptors to diabetic
retinopathy.  These  possibilities  remain  to  be  tested
experimentally.
Just as therapies were shown above to promote further
exacerbation of some diabetes-induced changes in transcript
levels, therapy-specific exacerbation of alternative splicing
also  occurs.  These  side  effects  were  more  prominent
following treatment with the p38 MAPK inhibitor than with
the RAGE inhibitor, but the significance of these differences
is not known at present. It warrants mention that alternatively
spliced transcripts have been identified in a variety of diseases
[62],  and  that  a  specific  spliced  form  of  a  gene  such  as
COX-1 is one target of acetaminophen [59].
In conclusion, we have applied RNA-seq strategy and two
analysis methods to determine the molecular signatures that
involve  representative  transcripts  of  retinal  vasculature,
inflammatory pathway, Wnt signaling, apoptosis, crystallins,
and  UDP-glucuronosyl  transferases.  The  importance  of
several of these abnormalities in the development of diabetic
retinopathy has been identified previously, illustrating the
power  of  the  RNA-seq  technique  to  identify  important
changes  in  disease.  Of  importance,  however,  is  the
identification  of  disease  and  treatment-specific  alternative
splicing by this strategy. The remarkable longevity of changes
observed in transcript levels during the 8 months of diabetes
in our study suggests that these changes may be necessary to
promote  and  maintain  the  complications  of  diabetes.  The
inhibitors of RAGE and p38 MAPK reversed some of the
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1142diabetes-induced levels of various transcripts to normal levels,
and exacerbated the changes in others. The significance and
mechanisms  underlying  these  alterations  remain  to  be
determined, but our results suggest RNA-seq as a desirable
strategy  for  investigating  the  pathogenesis  of  diabetic
retinopathy  or  other  diseases,  to  distinguish  between
candidate drugs and to determine their mechanisms of action.
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1145Appendix 1. Comparison of transcript abundance changes obtained by two
methods of analysis*.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file. *Method I (BWA-ANOVA) and
method  II  (ELAND-SAM)  have  been  described  in  the
methods’ section. Fold changes are calculated as a ratio of
transcripts in diabetic animals and nondiabetic controls.
Appendix 2. Treatment responsive alternatively spliced transcripts.
To access the data, click or select the words “Appendix
2.” This will initiate the download of a compressed (pdf)
archive  that  contains  the  file.  *Treatment  1=diabetic  plus
murine RAGE-Fc fusion protein, Treatment 2=diabetic plus
p38 MAPK inhibitor PHA666859.
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